Neuromuscular disorder as initial manifestation of secondary hyperparathyroidism – a case report

by Karim Hajjar, Tim Hagenacker
Published 2017-03-01

Editorial: Spinal Muscular Atrophy: Evolutions and Revolutions of Modern Therapy

by Richard S. Finkel, Ulrike Schara-Schmidt, Tim Hagenacker
Published 2020-07-01

Clinical features of neuromuscular disorders in patients with N-type voltage-gated calcium channel antibodies

by Andreas Totzeck, Petra Mummel, Oliver Kastrup, Tim Hagenacker
Published 2016-09-01

Understanding the burden of refractory myasthenia gravis

by Christiane Schneider-Gold, Tim Hagenacker, Nico Melzer, Tobias Ruck
Published 2019-02-01

Simultaneous paraneoplastic cerebellar degeneration, Lambert-Eaton syndrome and neuropathy associated with AGNA/anti-SOX1 and VGCC antibodies

by Jonas Feldheim, Cornelius Deuschl, Martin Glas, Christoph Kleinschnitz, Tim Hagenacker
Published 2021-05-01

CIDP, myasthenia gravis, and membranous glomerulonephritis – three autoimmune disorders in one patient: a case report

by Saskia Bolz, Andreas Totzeck, Kerstin Amann, Mark Stettner, Christoph Kleinschnitz, Tim Hagenacker
Published 2018-08-01

Diagnosing cardiac amyloidosis in every-day practice: A practical guide for the cardiologist

by Maria Papathanasiou, Alexander Carpinteiro, Christoph Rischpler, Tim Hagenacker, Tienush Rassaf, Peter Luedike
Published 2020-06-01

Modulation of Glutamate Transporter EAAT1 and Inward-Rectifier Potassium Channel K_ir4.1 Expression in Cultured Spinal Cord Astrocytes by Platinum-Based Chemotherapeutics

by Markus Leo, Linda-Isabell Schmitt, Rebecca Steffen, Andrea Kutritz, Christoph Kleinschnitz, Tim Hagenacker
Published 2021-06-01

Immunotherapies in chronic adhesive arachnoiditis - A case series and literature review

by Jana Hackert, Louisa Maßmann, Ulrich Sure, Michael Forsting, Christoph Kleinschnitz, Refik Pul, Tim Hagenacker
Published 2021-09-01

Short Latency Gray Matter Changes in Voxel-Based Morphometry following High Frequent Visual Stimulation

by Steffen Naegel, Tim Hagenacker, Nina Theysohn, Hans-Christoph Diener, Zaza Katsarava, Mark Obermann, Dagny Holle
Published 2017-01-01

Neurofilament Heavy Chain and Tau Protein Are Not Elevated in Cerebrospinal Fluid of Adult Patients with Spinal Muscular Atrophy during Loading with Nusinersen

by Andreas Totzeck, Benjamin Stolte, Kathrin Kizina, Saskia Bolz, Melina Schlag, Andreas Thimm, Christoph Kleinschnitz, Tim Hagenacker
Published 2019-10-01

Assessment of Bulbar Function in Adult Patients with 5q-SMA Type 2 and 3 under Treatment with Nusinersen

by Svenja Brakemeier, Benjamin Stolte, Andreas Thimm, Kathrin Kizina, Andreas Totzeck, Juan Munoz-Rosales, Christoph Kleinschnitz, Tim Hagenacker
Published 2021-09-01

Platinum-Based Drugs Cause Mitochondrial Dysfunction in Cultured Dorsal Root Ganglion Neurons

by Markus Leo, Linda-Isabell Schmitt, Patricia Küsterarent, Andrea Kutritz, Tienush Rassaf, Christoph Kleinschnitz, Ulrike B. Hendgen-Cotta, Tim Hagenacker
Published 2020-11-01

Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy

by Benjamin Stolte, Andreas Totzeck, Kathrin Kizina, Saskia Bolz, Lena Pietruck, Christoph Mönninghoff, Nika Guberina, Denise Oldenburg, Michael Forsting, Christoph Kleinschnitz, Tim Hagenacker
Published 2018-10-01

Clinical Implication of Dosimetry of Computed Tomography- and Fluoroscopy-Guided Intrathecal Therapy With Nusinersen in Adult Patients With Spinal Muscular Atrophy

by Kathrin Kizina, Benjamin Stolte, Andreas Totzeck, Saskia Bolz, Michael Fleischer, Christoph Mönninghoff, Nika Guberina, Denise Oldenburg, Michael Forsting, Christoph Kleinschnitz, Tim Hagenacker
Published 2019-11-01

Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy

by Saskia Bolz, Thivyah Ramakrishnan, Michael Fleischer, Elisabeth Livingstone, Benjamin Stolte, Andreas Thimm, Kathrin Kizina, Selma Ugurel, Christoph Kleinschnitz, Martin Glas, Lisa Zimmer, Tim Hagenacker
Published 2021-03-01

A Sum Score to Define Therapy-Refractory Myasthenia Gravis: A German Consensus

by Michael Schroeter, Benjamin Berger, Franz Blaes, Tim Hagenacker, Sebastian Jander, Julia Kaiser, Petra Kalischewski, De-Hyung Lee, Tobias Ruck, Ulrike Schara, Peter Urban, Andreas Meisel
Published 2021-02-01

Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?

by Anne Zaremba, Eleftheria Chorti, Finja Jockenhöfer, Saskia Bolz, Selma Sirin, Martin Glas, Jürgen C. Becker, Selma Ugurel, Alexander Roesch, Dirk Schadendorf, Elisabeth Livingstone, Tim Hagenacker, Lisa Zimmer
Published 2019-05-01

Gut bacterial microbiota in patients with myasthenia gravis: results from the MYBIOM study

by Andreas Totzeck, Elakiya Ramakrishnan, Melina Schlag, Benjamin Stolte, Kathrin Kizina, Saskia Bolz, Andreas Thimm, Mark Stettner, Julian R. Marchesi, Jan Buer, Christoph Kleinschnitz, Hedda Luise Verhasselt, Tim Hagenacker
Published 2021-08-01

Cognitive Impairment in Adult Patients with 5q-Associated Spinal Muscular Atrophy

by Kathrin Kizina, Yakup Akkaya, Daniel Jokisch, Benjamin Stolte, Andreas Totzeck, Juan Munoz-Rosales, Andreas Thimm, Saskia Bolz, Svenja Brakemeier, Refik Pul, Derya Aslan, Jana Hackert, Christoph Kleinschnitz, Tim Hagenacker
Published 2021-09-01